CHAPTER 8: Muscarinic Receptors Allosteric Modulation

Bruce J. Melancon, Corey R Hopkins

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

This chapter describes recent activity in the advancement of ligands and therapeutic lead compounds for the allosteric modulation of the muscarinic receptors and their potential utility as therapies for central nervous system (CNS) disorders. The chapter reviews the activity over the past five years of allosteric modulation of the muscarinic receptor subtypes M1 and M4, along with giving a brief overview of the M5 subtype. Due to concerns about off-target effects and toxicity with orthosteric modulators, much attention has concentrated on positive and negative allosteric modulators of these receptors in order to identify more selective lead compounds. Recent efforts have afforded a variety of improvements in potency and selectivity and pharmacokinetic properties that warrant further investigation and optimization.

Original languageEnglish (US)
Title of host publicationAllosterism in Drug Discovery
EditorsDario Doller
PublisherRoyal Society of Chemistry
Pages175-193
Number of pages19
Edition56
DOIs
StatePublished - Jan 1 2017

Publication series

NameRSC Drug Discovery Series
Number56
Volume2017-January
ISSN (Print)2041-3203
ISSN (Electronic)2041-3211

Fingerprint

Muscarinic Receptors
Muscarinic M4 Receptors
Muscarinic M1 Receptors
Central Nervous System Diseases
Pharmacokinetics
Ligands
Therapeutics
Lead

ASJC Scopus subject areas

  • Drug Discovery

Cite this

Melancon, B. J., & Hopkins, C. R. (2017). CHAPTER 8: Muscarinic Receptors Allosteric Modulation. In D. Doller (Ed.), Allosterism in Drug Discovery (56 ed., pp. 175-193). (RSC Drug Discovery Series; Vol. 2017-January, No. 56). Royal Society of Chemistry. https://doi.org/10.1039/9781782629276-00175

CHAPTER 8 : Muscarinic Receptors Allosteric Modulation. / Melancon, Bruce J.; Hopkins, Corey R.

Allosterism in Drug Discovery. ed. / Dario Doller. 56. ed. Royal Society of Chemistry, 2017. p. 175-193 (RSC Drug Discovery Series; Vol. 2017-January, No. 56).

Research output: Chapter in Book/Report/Conference proceedingChapter

Melancon, BJ & Hopkins, CR 2017, CHAPTER 8: Muscarinic Receptors Allosteric Modulation. in D Doller (ed.), Allosterism in Drug Discovery. 56 edn, RSC Drug Discovery Series, no. 56, vol. 2017-January, Royal Society of Chemistry, pp. 175-193. https://doi.org/10.1039/9781782629276-00175
Melancon BJ, Hopkins CR. CHAPTER 8: Muscarinic Receptors Allosteric Modulation. In Doller D, editor, Allosterism in Drug Discovery. 56 ed. Royal Society of Chemistry. 2017. p. 175-193. (RSC Drug Discovery Series; 56). https://doi.org/10.1039/9781782629276-00175
Melancon, Bruce J. ; Hopkins, Corey R. / CHAPTER 8 : Muscarinic Receptors Allosteric Modulation. Allosterism in Drug Discovery. editor / Dario Doller. 56. ed. Royal Society of Chemistry, 2017. pp. 175-193 (RSC Drug Discovery Series; 56).
@inbook{51f81f0805424028a9c6291e6b21ec68,
title = "CHAPTER 8: Muscarinic Receptors Allosteric Modulation",
abstract = "This chapter describes recent activity in the advancement of ligands and therapeutic lead compounds for the allosteric modulation of the muscarinic receptors and their potential utility as therapies for central nervous system (CNS) disorders. The chapter reviews the activity over the past five years of allosteric modulation of the muscarinic receptor subtypes M1 and M4, along with giving a brief overview of the M5 subtype. Due to concerns about off-target effects and toxicity with orthosteric modulators, much attention has concentrated on positive and negative allosteric modulators of these receptors in order to identify more selective lead compounds. Recent efforts have afforded a variety of improvements in potency and selectivity and pharmacokinetic properties that warrant further investigation and optimization.",
author = "Melancon, {Bruce J.} and Hopkins, {Corey R}",
year = "2017",
month = "1",
day = "1",
doi = "10.1039/9781782629276-00175",
language = "English (US)",
series = "RSC Drug Discovery Series",
publisher = "Royal Society of Chemistry",
number = "56",
pages = "175--193",
editor = "Dario Doller",
booktitle = "Allosterism in Drug Discovery",
address = "United Kingdom",
edition = "56",

}

TY - CHAP

T1 - CHAPTER 8

T2 - Muscarinic Receptors Allosteric Modulation

AU - Melancon, Bruce J.

AU - Hopkins, Corey R

PY - 2017/1/1

Y1 - 2017/1/1

N2 - This chapter describes recent activity in the advancement of ligands and therapeutic lead compounds for the allosteric modulation of the muscarinic receptors and their potential utility as therapies for central nervous system (CNS) disorders. The chapter reviews the activity over the past five years of allosteric modulation of the muscarinic receptor subtypes M1 and M4, along with giving a brief overview of the M5 subtype. Due to concerns about off-target effects and toxicity with orthosteric modulators, much attention has concentrated on positive and negative allosteric modulators of these receptors in order to identify more selective lead compounds. Recent efforts have afforded a variety of improvements in potency and selectivity and pharmacokinetic properties that warrant further investigation and optimization.

AB - This chapter describes recent activity in the advancement of ligands and therapeutic lead compounds for the allosteric modulation of the muscarinic receptors and their potential utility as therapies for central nervous system (CNS) disorders. The chapter reviews the activity over the past five years of allosteric modulation of the muscarinic receptor subtypes M1 and M4, along with giving a brief overview of the M5 subtype. Due to concerns about off-target effects and toxicity with orthosteric modulators, much attention has concentrated on positive and negative allosteric modulators of these receptors in order to identify more selective lead compounds. Recent efforts have afforded a variety of improvements in potency and selectivity and pharmacokinetic properties that warrant further investigation and optimization.

UR - http://www.scopus.com/inward/record.url?scp=85006386954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006386954&partnerID=8YFLogxK

U2 - 10.1039/9781782629276-00175

DO - 10.1039/9781782629276-00175

M3 - Chapter

AN - SCOPUS:85006386954

T3 - RSC Drug Discovery Series

SP - 175

EP - 193

BT - Allosterism in Drug Discovery

A2 - Doller, Dario

PB - Royal Society of Chemistry

ER -